Treatment of Vemurafenib-Resistant SKMEL-28 Melanoma Cells with Paclitaxel |
Nguyen, Dinh Thang
(Department of Biochemistry and Plant Physiology, Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Vietnam National University)
Phan, Tuan Nghia (Department of Biochemistry and Plant Physiology, Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Vietnam National University) Kumasaka, Mayuko Y. (Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine) Yajima, Ichiro (Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine) Kato, Masashi (Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine) |
1 | Atefi M, von Euw E, Attar N, et al (2011). Reversing melanoma cross-resistance to BRAF and MEK inhibitors by cotargeting the AKT/mTOR pathway. PLoS One, 6, 28973. DOI |
2 | Bhattacharya S, Darjatmoko SR, Polans AS (2011). Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res, 21, 180-7. DOI |
3 | Bollag G, Hirth P, Tsai J, et al (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467, 596-9. DOI |
4 | Bollag G, Tsai J, Zhang J, et al (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov, 11, 873-86. DOI |
5 | Chen B, Tardell C, Higgins B, et al (2012). BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One, 7, 42598. DOI |
6 | Cohen C, Zavala-Pompa A, Sequeira JH, et al (2002). Mitogenactived protein kinase activation is an early event in melanoma progression. Clin Cancer Res, 8, 3728-33. |
7 | Corcoran RB, Rothenberg SM, Hata AN, et al (2013). TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med, 5, 196-8. |
8 | Dankort D, Curley DP, Cartlidge RA, et al (2009). Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet, 415, 544-52. |
9 | Davies H, Bignell GR, Cox C, et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54. DOI |
10 | Dhawan P, Singh AB, Ellis DL, et al (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-egulation of nuclear factor-kappaB and tumor progression. Cancer Res, 62, 7335-42. |
11 | Flaherty KT, Puzanov I, Kim KB, et al (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 363, 809-19. DOI |
12 | Fontanini G, Vignati S, Bigini D, et al (1995). Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer, 31, 78-183. |
13 | Girotti MR, Marais R (2013). Deja vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov, 3, 487-90. DOI |
14 | Gray-Schopfer V, Wellbrock C, Marais R (2007). Melanoma biology and new targeted therapy. Nature, 445, 851-57. DOI |
15 | Johannessen CM, Boehm JS, Kim SY, et al (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468, 68-972. |
16 | Gross A, Niemetz-Rahn A, Nonnenmacher A, et al (2014). Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol, [Epub ahead of print]. |
17 | Guan H, Singh NP, Singh UP, et al (2012). Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One, 7, 35650. DOI |
18 | Halaban R, Zhang W, Bacchiocchi A, et al (2010). PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res, 23, 190-200. DOI |
19 | Joseph EW, Pratilas CA, Poulikakos PI, et al (2010). The RAF inhibitor PLX4032 inhibits ERK signalingand tumor cell proliferation in a V600E BRAF selective manner. Proc Natl Acad Sci U S A, 107, 14903-8. DOI |
20 | Kato M, Takeda K, Hossain K, et al (2010). A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation. J Cell Biochem, 110, 399-407. |
21 | Kawada K, Sonoshita M, Sakashita H, et al (2004). Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res, 64, 4010-7. DOI |
22 | Lassen A, Atefi M, Robert L, et al (2014). Comin-Anduix B, Ribas A. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer, 13, 83. DOI |
23 | Lucchetti C, Rizzolio F, Castronovo M, et al (2011). Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cells. Pharmacogenomics, 12, 1381. |
24 | Osmond GW, Masko EM, Tyler DS, et al (2013). In vitro and in vivo evaluation of resveratrol and 3, 5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. J Surg Res, 179, 141-8. DOI |
25 | McCubrey JA, Steelman LS, Chappell WH, et al (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773, 1263-84. DOI |
26 | Meier F, Schittek B, Busch S, et al (2005). The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci, 10, 2986-3001. DOI |
27 | Nazarian R, Shi H, Wang Q, et al (2010). Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature, 468, 973-7. DOI |
28 | Paraiso KH, Haarberg HE, Wood E, et al (2012). The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res, 18, 2502-14. DOI |
29 | Patel PS, Varney ML, Dave BJ, et al (2002). Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. J Interferon Cytokine Res, 22, 427-35. DOI |
30 | Peinado H, Aleckovic M, Lavotshkin S, et al (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med, 18, 883-91. DOI ScienceOn |
31 | Prahallad A, Sun C, Huang S, et al (2012). Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature, 483, 100-3. DOI |
32 | Shao Y, Aplin AE (2010). Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res, 70, 6670-81. DOI |
33 | Rebecca VW, Massaro RR, Fedorenko IV, et al (2014). Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res, 27, 465-78. DOI |
34 | Rigel DS (2010). Epidemiology of melanoma. Semin Cutan Med Surg, 29, 204-9. DOI |
35 | Schutte B, Nuydens R, Geerts H, et al (1998). Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods, 86, :63-9. DOI |
36 | Shin DH, Kim OH, Jun HS, et al (2008). Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway. Exp Mol Med, 40, 486-94. DOI |
37 | Shin H, Hong A, Kong X, et al (2013). A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov, 4, 69-79. |
38 | Smalley KS (2010). PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs, 11, 699-706. |
39 | Su F, Bradley WD, Wang Q, et al (2012). Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res, 72, 969-78. DOI |
40 | Sviderskaya E, Kallenberg DM, Bennett D (2010). The wellcome Trust functional genomics cell bank: holdings. Pigment Cell Melanoma Res, 23, 147-50. DOI |
41 | Thang ND, Yajima I, Kumasaka MY, et al (2011). Barium promotes Anchorage-independent growth and invasion of human HaCaT Keratinocytes via activation of c-SRC Kinase. PloS ONE, 6, 25636. DOI |
42 | Yajima I, Uemura N, Nizam S, et al (2012). Barium inhibits arsenic-mediated cell death in human squamous carcinoma cells. Arch Toxicol, 86, 961-73. DOI |
43 | Vergara D, Simeone P, Toraldo D, et al (2012). Resveratrol downregulates Akt/GSK and ERK signaling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst, 8, 1078-87. DOI |
44 | Wang J, Chen J, Miller DD, et al (2014). Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Mol Cancer Ther, 13, 16-26. |
![]() |